• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

    3/28/24 8:21:31 AM ET
    $ABTS
    $AKBA
    $AVTX
    $CC
    Computer Software: Programming Data Processing
    Technology
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABTS alert in real time by email

    Shares of RH (NYSE:RH) rose sharply in today’s pre-market trading following the release of quarterly results.

    RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company said it sees full-year 2024 demand growth of 12% to 14% and revenue growth of 8% to 10% on a year-over-year basis, according to data from Benzinga Pro.

    RH shares jumped 9.4% to $324.99 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Avalo Therapeutics, Inc. (NASDAQ:AVTX) rose 256.6% to $16.94 in pre-market trading after the company announced it acquired a Phase 2-ready anti-IL-1β mAb, which it refers to as AVTX-009, through the acquisition of privately held AlmataBio.
    • Binah Capital Group, Inc. (NASDAQ:BCG) gained 149% to $23.65 in pre-market trading after dipping more than 20% on Wednesday.
    • Kidpik Corp. (NASDAQ:PIK) gained 49.5% to $4.89 in pre-market trading.
    • Kidpik recently regained compliance with the Nasdaq minimum bid price requirement.
    • Kintara Therapeutics, Inc. (NASDAQ:KTRA) shares rose 36.3% to $0.1220 in pre-market trading. Kintara Therapeutics announced expansion of REM-001 clinical study to include patients on pembrolizumab.
    • Cazoo Group Ltd (NASDAQ:CZOO) gained 32.2% to $16.60 in pre-market trading after jumping over 100% on Wednesday.
    • Akebia Therapeutics, Inc. (NASDAQ:AKBA) shares rose 25% to $2.80 in pre-market trading. Akebia's received the FDA approval of Vafseo® tablets for dialysis-related anemia treatment.
    • Longeveron Inc. (NASDAQ:LGVN) gained 17% to $3.66 in pre-market trading. Longeveron’s board recently approved a 1-for-10 reverse split of Class A common stock.
    • 22nd Century Group, Inc. (NASDAQ:XXII) climbed 14.1% to $0.15 in pre-market trading. 22nd Century Group is expected to report quarterly earnings today.
    • GigaCloud Technology Inc. (NASDAQ:GCT) shares rose 9% to $28.50 in pre-market trading. GigaCloud Technology filed annual report on Form 10-K for fiscal year 2023.

    Losers

    • GCT Semiconductor Holding Inc, (NYSE:GCTS) dipped 21.2% to $34.68 in pre-market trading amid volatility following the company's recently completed business combination with Concord Acquisition Corp III and NYSE debut.
    • MillerKnoll, Inc. (NASDAQ:MLKN) shares fell 17.4% to $25.19 in pre-market trading as the company reported downbeat sales for its third quarter and issued weak guidance for the fourth quarter.
    • Gamida Cell Ltd. (NASDAQ:GMDA) shares tumbled 16.6% to $0.0494 in pre-market trading. Gamida Cell shares dipped over 82% on Wednesday after the company reported fourth-quarter results and disclosed the commencement of a restructuring process.
    • urban-gro, Inc. (NASDAQ:UGRO) declined 16.3% to $1.5196 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.
    • Movella Holdings Inc. (NASDAQ:MVLA) fell 15.2% to $0.0640 pre-market trading after dipping 20% on Wednesday.
    • NuCana plc (NASDAQ:NCNA) fell 13.4% to $0.2702 in pre-market trading. NuCana announced a plan to implement 1-for-25 ADS ratio change.
    • The Chemours Company (NYSE:CC) shares dropped 10% to $26.00 in pre-market trading after the company reported fourth-quarter results. The company also disclosed material weaknesses and remediation plan .
    • Abits Group Inc. (NASDAQ:ABTS) fell 9.2% to $0.7083 in pre-market trading.
    • Hitek Global Inc. (NASDAQ:HKIT) fell 8.1% to $1.60 in pre-market trading after gaining over 22% on Wednesday.
    • SOBR Safe, Inc. (NASDAQ:SOBR) fell 8% to $0.46 pre-market trading after gaining 12% on Wednesday.

     

    Now Read This: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday

     

    Get the next $ABTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABTS
    $AKBA
    $AVTX
    $CC

    CompanyDatePrice TargetRatingAnalyst
    Avalo Therapeutics Inc.
    $AVTX
    4/9/2026$48.00Outperform
    Wolfe Research
    Avalo Therapeutics Inc.
    $AVTX
    4/6/2026$52.00Mkt Outperform
    Citizens
    RH
    $RH
    3/25/2026$185.00 → $165.00Market Perform
    Telsey Advisory Group
    MillerKnoll Inc.
    $MLKN
    2/10/2026Outperform
    William Blair
    Avalo Therapeutics Inc.
    $AVTX
    2/2/2026$50.00Buy
    Guggenheim
    Avalo Therapeutics Inc.
    $AVTX
    12/18/2025$39.00Outperform
    Mizuho
    RH
    $RH
    12/12/2025$165.00Buy → Hold
    Stifel
    RH
    $RH
    12/12/2025$220.00 → $185.00Market Perform
    Telsey Advisory Group
    More analyst ratings

    $ABTS
    $AKBA
    $AVTX
    $CC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Avalo Therapeutics with a new price target

    Wolfe Research initiated coverage of Avalo Therapeutics with a rating of Outperform and set a new price target of $48.00

    4/9/26 8:40:45 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Citizens initiated coverage on Avalo Therapeutics with a new price target

    Citizens initiated coverage of Avalo Therapeutics with a rating of Mkt Outperform and set a new price target of $52.00

    4/6/26 8:44:25 AM ET
    $AVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Telsey Advisory Group reiterated coverage on RH with a new price target

    Telsey Advisory Group reiterated coverage of RH with a rating of Market Perform and set a new price target of $165.00 from $185.00 previously

    3/25/26 8:14:41 AM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and President Butler John P. bought $86,588 worth of shares (69,270 units at $1.25), increasing direct ownership by 2% to 3,367,064 units (SEC Form 4)

    4 - Akebia Therapeutics, Inc. (0001517022) (Issuer)

    3/5/26 6:55:46 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Baluch Khoso bought 11,766 shares, increasing direct ownership by 29% to 52,516 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:07 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Locklear Lisa bought 11,766 shares, increasing direct ownership by 5% to 250,964 units (SEC Form 4)

    4 - Longeveron Inc. (0001721484) (Issuer)

    8/13/25 6:00:08 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VAFSEO issued to AKEBIA THERAPEUTICS INC

    Submission status for AKEBIA THERAPEUTICS INC's drug VAFSEO (ORIG-1) with active ingredient VADADUSTAT has changed to 'Approval' on 03/27/2024. Application Category: NDA, Application Number: 215192, Application Classification: Type 1 - New Molecular Entity

    3/28/24 10:46:38 AM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    April 17, 2023 - FDA Approves Cell Therapy for Patients with Blood Cancers to Reduce Risk of Infection Following Stem Cell Transplantation

    For Immediate Release: April 17, 2023 Today, the U.S. Food and Drug Administration approved Omisirge (omidubicel-onlv), a substantially modified allogeneic (donor) cord blood-based cell therapy to quicken the recovery of neutrophils (a subset of white blood cells) in the body and reduce the risk of infection. The product is intended for use in adults and pediatric patients 12 years and older with blood cancers p

    4/17/23 1:02:15 PM ET
    $GMDA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    December 23, 2021 - FDA Authorizes Marketing of Tobacco Products that Help Reduce Exposure to and Consumption of Nicotine for Smokers Who Use Them

    For Immediate Release: December 23, 2021 Today, the U.S. Food and Drug Administration authorized the marketing of 22nd Century Group Inc.’s “VLN King” and “VLN Menthol King” combusted, filtered cigarettes as modified risk tobacco products (MRTPs), which help reduce exposure to, and consumption of, nicotine for smokers who use them. These are the first combusted cigarettes to be authorized as MRTPs and the second

    12/23/21 9:06:12 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Deng Conglin

    4 - Abits Group Inc (0001864055) (Issuer)

    4/17/26 9:35:27 PM ET
    $ABTS
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Preston Jack M

    4 - RH (0001528849) (Issuer)

    4/16/26 8:30:06 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    SEC Form 4 filed by Demilio Mark S

    4 - RH (0001528849) (Issuer)

    4/16/26 8:30:13 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    22nd Century Group Expands Reduced Nicotine Platform Through New Testing Services Agreement with North Carolina State University

    MOCKSVILLE, N.C., April 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (NASDAQ:XXII), a tobacco products company focused on nicotine reduction and plant biotechnology, today announced corporate updates regarding a new testing services agreement with North Carolina State University aimed at validating tobacco varieties featuring improved leaf quality and increased crop yields with the same low-nicotine content. The initiative builds upon 22nd Century's proprietary reduced nicotine content technology platform, which utilizes advanced plant breeding and biotechnology to reduce nicotine content in tobacco to minimally addictive levels. The Company's reduced nicotine tobacco is the foun

    4/23/26 7:50:00 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms July 10 – August 5, 2026 and Four Venues for Lanka Premier League Season 6; Tournament Conducted in Partnership with UGRO Subsidiary IPG Group

    LAFAYETTE, Colo., April 23, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), operating through Flash Sports & Media, Inc., today noted the official announcement by Sri Lanka Cricket ("SLC") confirming the dates, venues, and player-registration timeline for Lanka Premier League ("LPL") Season 6. The tournament will run from July 10 to August 5, 2026, and is owned by SLC and conducted in partnership with Innovative Production Group FZ, LLC ("IPG"), the event rights holder. The Company participates in the tournament through its subsidiary, IPG under existing commercial arrangements. Season 6 — By the Numbers Tournament windowJuly 10 – August 5, 2026 (

    4/23/26 7:05:00 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    SEC Filings

    View All

    GigaCloud Technology Inc filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - GigaCloud Technology Inc (0001857816) (Filer)

    4/22/26 5:08:36 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form SCHEDULE 13G filed by Abits Group Inc

    SCHEDULE 13G - Abits Group Inc (0001864055) (Subject)

    4/22/26 9:00:15 AM ET
    $ABTS
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form 10-K/A filed by urban-gro Inc.

    10-K/A - urban-gro, Inc. (0001706524) (Filer)

    4/21/26 4:32:00 PM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Leadership Updates

    Live Leadership Updates

    View All

    urban-gro, Inc. (Nasdaq: UGRO) — Sri Lanka Cricket Confirms July 10 – August 5, 2026 and Four Venues for Lanka Premier League Season 6; Tournament Conducted in Partnership with UGRO Subsidiary IPG Group

    LAFAYETTE, Colo., April 23, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), operating through Flash Sports & Media, Inc., today noted the official announcement by Sri Lanka Cricket ("SLC") confirming the dates, venues, and player-registration timeline for Lanka Premier League ("LPL") Season 6. The tournament will run from July 10 to August 5, 2026, and is owned by SLC and conducted in partnership with Innovative Production Group FZ, LLC ("IPG"), the event rights holder. The Company participates in the tournament through its subsidiary, IPG under existing commercial arrangements. Season 6 — By the Numbers Tournament windowJuly 10 – August 5, 2026 (

    4/23/26 7:05:00 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    urban-gro, Inc. (Nasdaq: UGRO) Announces Lanka Premier League Season 6 — Potential Record 600-Player Pool, World-Class Marquee Talent, and Expected Appointment of Chris Gayle as Global Brand Ambassador

    LAFAYETTE, Colo., April 13, 2026 (GLOBE NEWSWIRE) -- urban-gro, Inc. (NASDAQ:UGRO) ("urban-gro" or the "Company"), operating through Flash Sports & Media, Inc., a vertically integrated sports, media, and experiential platform, today announced that Lanka Premier League ("LPL") Season 6 — executed via its subsidiary Innovative Production Group FZ, LLC ("IPG") platform — is expecting record-breaking expansion. Season 6 is projected to feature the largest-ever LPL player registration pool of 500 to 600 athletes expected to be drawn from the world's top cricketing nations, elevated by a marquee roster of global superstars and the expected appointment of T20 legend Chris Gayle as official Brand

    4/13/26 7:05:00 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary

    Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors

    CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (NASDAQ:AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the appointment of biopharmaceutical leader Philip J. Vickers to its Board of Directors, effective April 1, 2026. Dr. Vickers is the President and Chief Executive Officer and a member of the Board of Directors of Solu Therapeutics, a venture-backed biotechnology company focused on creating first-in-class therapeutics utilizing a novel drug discovery platform, and he has held senior leadership positions at several early-stage biotechnology companies as well as global pharmaceutica

    4/1/26 4:05:00 PM ET
    $AKBA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABTS
    $AKBA
    $AVTX
    $CC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by GigaCloud Technology Inc

    SC 13D/A - GigaCloud Technology Inc (0001857816) (Subject)

    12/12/24 3:02:53 PM ET
    $GCT
    Catalog/Specialty Distribution
    Consumer Discretionary

    Amendment: SEC Form SC 13G/A filed by 22nd Century Group Inc.

    SC 13G/A - 22nd Century Group, Inc. (0001347858) (Subject)

    12/3/24 11:18:54 AM ET
    $XXII
    Medicinal Chemicals and Botanical Products
    Health Care

    Amendment: SEC Form SC 13D/A filed by Abits Group Inc

    SC 13D/A - Abits Group Inc (0001864055) (Subject)

    11/21/24 6:05:10 PM ET
    $ABTS
    Computer Software: Programming Data Processing
    Technology

    $ABTS
    $AKBA
    $AVTX
    $CC
    Financials

    Live finance-specific insights

    View All

    The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

    Issued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi

    4/23/26 6:15:00 AM ET
    $LGVN
    $LLY
    $NVO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chemours Announces Dates for First Quarter 2026 Earnings Release and Webcast Conference Call

    WILMINGTON, Del., April 21, 2026 /PRNewswire/ -- The Chemours Company ("Chemours" or "the Company") (NYSE:CC) today announced that the Company expects to issue its first quarter 2026 financial results after market on Tuesday, May 5, 2026.The Company expects to hold its conference call to discuss its first quarter 2026 financial results at 8:00 a.m. Eastern Time on Wednesday, May 6, 2026. The call is open to the public and can be accessed via the webcast information below. The webcast and materials can be accessed by visiting the "Events and Presentations" section of the Investor Relations section of Chemours' website at investors.chemours.com.Conference Call: Please visit investors.chemours.

    4/21/26 4:30:00 PM ET
    $CC
    Major Chemicals
    Industrials

    RH to Report Fourth Quarter and Fiscal Year 2025 Financial Results on March 31, 2026

    RH (NYSE:RH) today announced that it will report financial results for the fourth quarter and fiscal year 2025 ended January 31, 2026, on Tuesday, March 31, 2026, after market close. RH's fourth quarter and fiscal year 2025 financial results will include a video presentation from Gary Friedman, RH Chairman and Chief Executive Officer, highlighting the Company's continued evolution and recent performance. The video presentation will be posted to the Company's investor relations website at ir.rh.com. RH leadership will host a live webcast of the video presentation followed by Q&A at 2:00 pm Pacific Time (5:00 pm Eastern Time) on March 31, 2026, at ir.rh.com. A replay will also be available

    3/26/26 4:05:00 PM ET
    $RH
    Other Specialty Stores
    Consumer Discretionary

    $ABTS
    $AKBA
    $AVTX
    $CC
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at urban-gro Inc. on Jun 6

    Urban-gro Inc. saw an interesting insider purchase on June 6, 2024, when Wilks Lewis bought $29,000 worth of shares, acquiring 20,000 units at a price of $1.45 per unit. This transaction increased Lewis' direct ownership by 12% to 184,108 units, as reported in SEC Form 4. Insider transactions like this can provide valuable insights for investors, indicating confidence in the company's future prospects. Analyzing the insider activity surrounding Urban-gro Inc., we can observe several transactions that may reveal patterns or insights. Looking back at previous filings, on September 1, 2023, Wilks Lewis purchased $10,300 worth of shares, acquiring 10,000 units at $1.03 per unit. This

    6/10/24 12:49:49 AM ET
    $UGRO
    Industrial Specialties
    Consumer Discretionary